Page last updated: 2024-11-12

p 829

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

P 829: amino acid sequence in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9898619
CHEMBL ID	1908335
CHEBI ID	135908
SCHEMBL ID	456503
MeSH ID	M0263746

Synonyms (33)

Synonym
161982-62-3
depreotide (usan/inn)
D03687
CHEBI:135908
p-829
unii-ndp0h8e844
ndp0h8e844 ,
p 829
lysyl-cysteinyl-lysyl-(beta-dap) cyclo(homocysteinyl-(n-methyl)phenylalanyl-tyrosyl-tryptophyl-lysyl-valyl)thiomethyl ketone
cyclo(l-homocysteinyl-n-methyl-l-phenylalanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl) (1-1')-sulfide with 3-((mercaptoacetyl)amino)-l-alanyl-l-lysyl-l-cysteinyl-l-lysinamide
cyclo(l-homocysteinyl-n-methyl-l-phenylalanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl), (1-1')-sulfide with 3-(2-mercaptoacetamido)-l-alanyl-l-lysyl-l-cysteinyl-l-lysinamide
p829 cpd
depreotide [usan:inn]
lys-cys-lys-(beta-dap)-ch2co-s-cyclo(hcys-(n-me)phe-tyr-trp-lys-val)
p829
depreotide
cyclo(l-homocysteinyl-n-methyl-l-phenylalanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl), (1-1')-thioether with 3-((mercaptoacetyl)amino)-l-alanyl-l-lysyl-l-cysteinyl-l-lysinamide
CHEMBL1908335
depreotide [usan]
cyclo(l-homocysteinyl-n-methyl-l-phenylalanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl), (1->1')-sulfide with 3-(2-mercaptoacetamido)-l-alanyl-l-lysyl-l-cysteinyl-l-lysinamide
depreotide [inn]
cyclo(l-homocysteinyl-n-methyl-l-phenylalanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl), (1->1')-sulphide with 3-(2-mercaptoacetamido)-l-alanyl-l-lysyl-l-cysteinyl-l-lysinamide
cyclo(l-homocysteinyl-n-methyl-l-phenylalanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl) (1->1')-sulphide with 3-((mercaptoacetyl)amino)-l-alanyl-l-lysyl-l-cysteinyl-l-lysinamide
depreotide [who-dd]
depreotide [mi]
cyclo(l-homocysteinyl-n-methyl-l-phenylalanyl-l-tyrosyl-d-tryptophyl-l-lysyl-l-valyl) (1->1')-sulfide with 3-((mercaptoacetyl)amino)-l-alanyl-l-lysyl-l-cysteinyl-l-lysinamide
SCHEMBL456503
DB11628
(2s)-6-amino-2-[[(2r)-2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-[[2-[2-[(2s,5s,8s,11r,14s,17s)-14-(4-aminobutyl)-5-benzyl-8-[(4-hydroxyphenyl)methyl]-11-(1h-indol-3-ylmethyl)-4-methyl-3,6,9,12,15,18-hexaoxo-17-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]
Q27284812
DTXSID301026951
CS-0069943
HY-114133

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
oligopeptide	A peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID297465	Ratio of drug level in tumor to muscle of rat AR42J tumor bearing mouse	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.
AID297463	Biodistribution in tumor of rat AR42J tumor bearing mouse	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.
AID297466	Biodistribution in tumor of rat AR42J tumor bearing mouse in presence of octreotide	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.
AID297462	Displacement of [125I]somatostatin from SSTR in rat AR42J cells	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.
AID297464	Ratio of drug level in tumor to blood of rat AR42J tumor bearing mouse	2007	Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18	Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (50.00)	18.2507
2000's	4 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	27.74 (24.57)
Research Supply Index	2.48 (2.92)
Research Growth Index	4.27 (4.65)
Search Engine Demand Index	26.69 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (27.74)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (37.50%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (62.50%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	1.99	1	0	pentacarboxylic acid	copper chelator
rhenium Rhenium: A metal, atomic number 75, atomic weight 186.207, symbol Re.	2.4	2	0	manganese group element atom
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	3.79	2	1	manganese group element atom
(dtpa-phe(1))-octreotide SDZ 215-811: potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors	1.99	1	0
sodium pertechnetate tc 99m Sodium Pertechnetate Tc 99m: A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints.	1.99	1	0

Condition	Relationship Strength	Studies	Trials
Benign Neoplasms [description not available]	2.42	2	0
Cancer of Pancreas [description not available]	2.41	2	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.42	2	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.41	2	0
Basedow Disease [description not available]	3.4	1	1
Cancer of Lung [description not available]	4.86	4	2
Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).	3.4	1	1
Lung Neoplasms Tumors or cancer of the LUNG.	4.86	4	2
Breast Cancer [description not available]	2.4	2	0
Malignant Melanoma [description not available]	1.99	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.4	2	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.99	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	3.79	2	1
Carcinoma, Oat Cell [description not available]	3.38	1	1
Carcinoma, Non-Small Cell Lung [description not available]	3.38	1	1
Coin Lesion, Pulmonary [description not available]	3.38	1	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.38	1	1
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	3.38	1	1
Argentaffinoma [description not available]	3.39	1	1
Carcinoid Tumor A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)	3.39	1	1
Zollinger-Ellison Syndrome A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.	3.39	1	1
Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.	3.39	1	1

chemdatabank.com